If you have been reading about freeze-thaw and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-16. Numbers and descriptions here follow the published literature rather than marketing material.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
=== Expansion and loss === Typical GSH-Px and superoxide dismutase enzymes requrire trace elements including selenium, vanadium, magnesium, copper, and zinc. These elements tend to be abundant in marine environments but can be lacking in some terrestrial mineral-deficient areas. Organisms have accordingly expanded or reduced their seleno-proteomes (arsenal of selenoproteins) to adapt to the situation. As land plants adapted to the terrestrial environment from about 500 million years ago, they too faced the problem of a lack of these elements. Accordingly, most land plants do not produce selenoproteins. For their anti-oxidation needs, they slowly optimized the production of "new" endogenous antioxidants such as ascorbic acid (Vitamin C), polyphenols (including flavonoids), tocopherols, etc. A few of these appeared more recently, in the last 50–200 million years, in fruits and flowers of angiosperm plants. In fact, the angiosperms (the dominant type of plant today) and most of their antioxidant pigments evolved during the late Jurassic period. The vertebrates of 500 million years ago were marine fishes. They opted to expand their seleno-proteomes, most notably evolving a thyroid gland with high concentration of selenium and iodine and associated systems. A group of them, the tetrapoda, later adapted to life on land but retained many of the ancestral selenoproteins.
Cannabinoids, or cannabinoid receptor agonists, such as the δ9-tetrahydrocannabinol (THC) found in cannabis, have been found to be effective in improving sleep in healthy people and in people with insomnia. They have been found to improve sleep onset, sleep duration, and sleep quality. Cannabidiol (CBD), which acts differently than other cannabinoids like THC, is not effective in improving sleep on the other hand. Zenivol is a cannabis extract which is approved for the treatment of insomnia in Germany.
=== Lawsuit === Fenn's work with electrospray ionization was at the center of a lawsuit pitting him against his alma mater and former employer, Yale University. His initial dispute with the university began in 1987, when he turned 70 – Yale's mandatory retirement age. Per university policy, Fenn was made an emeritus professor, which resulted in a reduction to his lab space. Emeritus professors at Yale are still provided with an office, but cannot conduct their own research, nor manage their own labs. In 1989, when Yale University inquired about the progress and potential about his electrospray work, he downplayed its potential scientific and commercial value. Fenn believed he had the rights to the invention under the Bayh–Dole Act. Fenn patented the technology on his own, and sold licensing rights to a company he partly owned – Analytica of Branford. In 1993, a private company seeking to license the use of electrospray technology traced its invention to Yale, when the university discovered that Fenn held the patent. Yale's policy regarding patents generated by faculty or students requires that a percentage of any royalties generated from the patent are used by the university to fund future research. They do not claim the rights to patents that are produced away from university facilities or not related to the researcher's "designated activities." Fenn claimed that he owned the technology because the work was completed after he had been forced to downsize at the university's mandatory retirement age.
== See also == Attack rate Basic reproduction number Flatten the curve List of COVID-19 simulation models Mathematical modelling in epidemiology Modifiable areal unit problem Next-generation matrix Risk assessment
Sources: en.wikipedia.org
==== IEC/RPLC ==== IEC/RP MMC combines the advantages of RPLC and IEC. For example, WAX/RP has increased separation power and degree of freedom in adjusting the separation selectivity when compared with single WAX or RPLC.
While there is limited literature on radiation injury to animals, there is no evidence of other types of radiation injury. Diagnostic radiation has been shown to cause local burns in animals, typically resulting from prolonged exposure of body parts or sparks from old x-ray tubes. It is important to note that the frequency of injury to veterinary staff and veterinarians is significantly lower than that in human medicine, highlighting the safety of diagnostic radiation in veterinary practice. In veterinary medicine, fewer images are taken compared to human medicine, particularly fewer CT scans. However, due to the manual restraint of animals to avoid anesthesia, at least one person is present in the control area, resulting in significantly higher radiation exposure than that of human medical staff. It is important to note that since the 1970s, dosimeters have been used to measure the radiation exposure of veterinary personnel, ensuring their safety. Feline hyperthyroidism (overactive thyroid) is a common disease in older cats. Radioiodine therapy is considered by many authors to be the treatment of choice. Following the administration of radioactive iodine, cats are kept in an isolation pen. The cat's radioactivity is measured to determine the time of discharge, which is typically 14 days after the start of therapy. The therapy requires significant radiation protection measures and is currently only offered at two veterinary facilities in Germany (as of 2010).
Proteomic profiling is the large-scale analysis of proteins, which is essential for understanding biological processes and disease mechanisms. A proteomic profile may be employed to discover or diagnose diseases or conditions, which can monitor responses to therapeutic measures. Sometimes, it is also referred to as a protein expression profile and protein signature. Proteome profiling analysis is the analysis of the entire proteome from complex samples such as complete cells, tissues, and body fluids. It is most used for identifying as many peptides and proteins as possible. Proteome profiling analysis based on mass spectrometry (MS) can provide reference information for high-throughput quantitative proteomics and protein modification analysis. Recent studies have compared various platforms, such as SomaScan and Olink, and highlighted differences in precision, accuracy, and phenotypic associations across diverse cohorts.
4He* → n + 3He + 3.3 MeV (ratio=50%) 4He* → p + 3H + 4.0 MeV (ratio=50%) 4He* → 4He + γ + 24 MeV (ratio=10−6) Only about one in a million of the intermediaries take the third pathway, making its products very rare compared to the other paths. This result is consistent with the predictions of the Bohr model. If 1 watt (6.242 × 1018 eV/s) were produced from ~2.2575 × 1011 deuteron fusions per second, with the known branching ratios, the resulting neutrons and tritium (3H) would be easily measured. Some researchers reported detecting 4He but without the expected neutron or tritium production; such a result would require branching ratios strongly favouring the third pathway, with the actual rates of the first two pathways lower by at least five orders of magnitude than observations from other experiments, directly contradicting both theoretically predicted and observed branching probabilities. Those reports of 4He production did not include detection of gamma rays, which would require the third pathway to have been changed somehow so that gamma rays are no longer emitted. The known rate of the decay process together with the inter-atomic spacing in a metallic crystal makes heat transfer of the 24 MeV excess energy into the host metal lattice prior to the intermediary's decay inexplicable by conventional understandings of momentum and energy transfer, and even then there would be measurable levels of radiation. Also, experiments indicate that the ratios of deuterium fusion remain constant at different energies.
=== Past === Nicaragua (1985–1990 for aggressive activities in Central America) South Africa (1985–1991 for maintaining apartheid) Libya (1986–2004 for sponsoring terrorism) Panama (1988–1990 against the Manuel Noriega government) Kuwait (1990–1991, while occupied by Iraq) Iraq (1990–2004 for invading Kuwait) Haiti (1991–1994 for the 1991 Haitian coup d'état) Serbia and Montenegro (1992–2003 for sponsoring Serb nationalist groups) UNITA (1993–2003 for interfering with UN peacekeeping efforts) Myanmar (1997–2016 against the policies of the military government) Afghanistan (1999–2002 for harboring al-Qaeda) Russia (2000–2012 to support the Megatons to Megawatts Program) Sierra Leone (2001–2004 for human rights violations) Liberia (2001–2015 directed against President Charles G. Taylor) Zimbabwe (2003–2024 against the ZANU–PF government) Syria (2004–2025 against the Bashar al-Assad government) Côte d'Ivoire (2006–2016 regarding the First Ivorian Civil War) International Criminal Court (2020–2021 for investigating actions by United States personnel in Afghanistan) West Bank settlers (2024–2025 for violence against Palestinians)
Sources: en.wikipedia.org
Wang, N.; He, Y.; Liu, S.; Makarcyzk, M. J.; Lei, G.; Chang, A.; Alexander, P. G.; Hao, T.; Padget, A. M.; De Pedro, N.; Menelaos, T.; Lin, H. (2022). "Engineering Osteoarthritic Cartilage Model". Science China Life Sciences. 65 (2): 309–327. doi:10.1007/s11427-021-1933-7. PMC 10077511. PMID 34109475. S2CID 235393377. Jogi, R.; Tager, M. J.; Perez, D.; Tsapekos, M. (2021). "Bovine Colostrum, Telomeres and Skin aging". Journal of Drugs in Dermatology. 20 (5): 538–545. doi:10.36849/JDD.5851. PMID 33938706. Shafa, M.; Walsh, T.; Panchalingam, K. M.; Richardson, T.; Menendez, L.; Tian, X.; Suresh Babu, S.; Dadgar, S.; Beller, J.; Yang, F.; Baghbaderani, B. A. (2019). "Long-term Stability and Differentiation Potential of Cryopreserved CGMP-compliant Human Induced Pluripotent Stem Cells". International Journal of Molecular Sciences. 21 (1): 108. doi:10.3390/ijms21010108. PMC 6982271. PMID 31877913. Samuel, P.; Tsapekos, M.; De Pedro, N.; Liu, A. G.; Casey Lippmeier, J.; Chen, S. (2022). "Ergothioneine Mitigates Telomere Shortening under Oxidative Stress Conditions". Journal of Dietary Supplements. 19 (2): 212–225. doi:10.1080/19390211.2020.1854919. PMID 33287595. S2CID 227953602. Mehkri, S.; Perez, Diego; Najarro, Pilar; Tsapekos, Menelaos; Bopanna, K. N. (July 2019). "Effect of Lutein (Lute-gen®) on Proliferation Rate and Telomere Length In Vitro and Possible Mechanism of Action". International Journal of Biology Research. 4 (3): 84–91. Phillippe, M.; Sawyer, M. R.; Edelson, P. K. (2019). "The Telomere Gestational Clock". American Journal of Obstetrics and Gynecology.
== D == Dakin reaction (AKA Dakin oxidation) Dakin–West reaction Danheiser annulation Danheiser benzannulation Darapsky degradation Darzens condensation, Darzens–Claisen reaction, Glycidic ester condensation Darzens halogenation Darzens synthesis of unsaturated ketones Darzens tetralin synthesis Davis' reagent, Davis oxidation Davis–Beirut reaction De Kimpe aziridine synthesis Dehydration reaction Dehydrogenation Delépine reaction DeMayo reaction Demjanov rearrangement Demjanow desamination Dess–Martin oxidation Diazoalkane 1,3-dipolar cycloaddition Diazotisation DIBAL-H selective reduction Dieckmann condensation Dieckmann reaction Diels–Alder reaction Diels–Reese reaction Dienol–benzene rearrangement Dienone–phenol rearrangement Dimroth rearrangement Di-π-methane rearrangement Directed ortho metalation Doebner modification Doebner reaction Doebner–Miller reaction, Beyer method for quinolines Doering–LaFlamme carbon chain extension Dötz reaction Dowd–Beckwith ring expansion reaction Duff reaction Dutt–Wormall reaction Dyotropic reaction
== History == Tenascin-X (TNX) protein was discovered during studies of human steroidogenesis and its disorders, particularly in patients with 21-hydroxylase deficiency, rather than during studies of connective tissue disorders. Researchers sequenced a 2.7 kb cDNA clone that showed similarities to tenascin, leading to the identification of the XB gene. This gene was initially called "Gene X" because its nature and function were unknown at the time. Further research revealed that this gene encodes the Tenascin-X protein, which belongs to the family of tenascins.
== Dental considerations == The protocols suggest the use of factor concentrate along with the use of local hemostatic techniques, such as suturing, and local measures, such as the use of oxidized cellulose, for example, Surgicel or fibrin glue in conjunction with post-operatively administered antifibrinolytic agents where appropriate. The use of any non-steroidal anti-inflammatory drug (NSAID) must be discussed beforehand with the patient's hematologist because of their effect on platelet aggregation. There are no restrictions regarding the type of local anaesthetic agent used although those with vasoconstrictors may provide additional local hemostasis.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.